Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population‐based cohort study

Evans syndrome in adults ‐ incidence, prevalence, and survival in a nationwide cohort

“…The risk of thrombosis in patients with AIHA, ITP, or ES was previously reported to be high in absolute terms, and compared to the risk in the general population . Our findings on the causes of death were ambiguous regarding cardiovascular‐related deaths, which included thromboembolic related deaths.…”

Is ITP a thrombophilic disorder?

“…A trend for higher risk also appears in some subgroups, but usually without reaching statistical significance. In particular, no significant higher risk for splenectomized patients can be derived from these studies, apart from a seemingly higher risk for VTE in Nøorgard et al, mostly for the insufficient power of the studies [15]. The increased risk is more evident in older than 50s-60s, but again the studies have no power to show significant differences according to age subgroups.…”

“…To partially overcome this limitation, only annualized risk should be considered. In the studies mentioned in Table I, including patients treated before the availability of TPO-ra, the annualized risk of VTE in ITP patients seems consistently variable between 0.41 and 0.67, despite the different study designs, compared with a correspondent range in control population variable from 0.20 to 0.42 in the three studies with matched controls [12,13,15]. Enger's study did not seem to sufficiently describe the design for selecting matched control population, so the figure of 0.09 3 100 patient-years should be taken with caution in the calculation of IRR [16].…”

“…In summary, all population-based studies using either patients without ITP registered in clinical practice [12] or matched subjects from general population [13,15,16] show evidence that the risk for VTE is higher (around two times) in chronic ITP compared with controls. A trend for higher risk also appears in some subgroups, but usually without reaching statistical significance.…”

“…Recently, a Scandinavian population-based cohort study was conducted by Nøorgard et al to assess if the thrombotic risk varies according to gender, age and level of comorbidity in cITP patients [15]. Incidence data for thrombosis were obtained from 1,821 patients with cITP taken from the National Health Registry Systems per 100 person-years, respectively) without reaching statistical significance, but the incidence of VTE was similar in both genders.…”